Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (15811)	2/24/1998 8:56:00 PM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

All, I think this whole issue of how you figure out what a drug is used for and compute royalties is pretty simple to settle. Suppose you had a drug that was marketed under a single brand name for multiple indications. Also suppose that royalties need to be split according to the indication. All you need to do is to periodically draw a random sample and check out that sample. That allows you to get an estimate that is as good as you like. I would expect that this issue has already been addressed in the various contracts. I would also consider the lawyers remiss if they have not addressed such a fundamental issue since this would inevitably result in litigation at some point in the future. And companies do not like litigation. Cheers, Torben